Mochi Health vs Brello: Coverage, Cash-Pay, and Access

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This comparison lives in the PlexusDx Education Hub, where we cover GLP-1 therapy, weight-management protocols, and the genetics that influence results. Open the Peptides & GLP-1 hub.

Independent editorial analysis. PlexusDx has no commercial relationship with Mochi Health or Brello, and there are no affiliate links, referral fees, or sponsorships involved.

Mochi Health and Brello approach GLP-1 access from two different directions — one builds in insurance support, the other centers on cash-pay compounded medication. That contrast is the most useful lens for comparing them, because it shapes what you pay and how you get treated. Here is how each works, plus a metabolic factor neither addresses. As of April 2026.

Two front doors to the same drug class

The core difference between these programs is the access model. Mochi leans on insurance support to help offset cost where a plan allows; Brello concentrates on a compounding-pharmacy pathway that is typically paid out of pocket. The same GLP-1 medications sit at the end of both routes — the route itself is what varies. Establishing which door you are walking through is the single most useful step before you weigh anything else about the two programs.

Inside Mochi Health's approach

Mochi Health (Mochi Health) runs as telehealth with insurance support. A program like this pairs a virtual evaluation with a provider-issued prescription that may go to a retail pharmacy for FDA-approved product or to a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Current details are on Mochi Health's official website.

Inside Brello's approach

Brello is structured around telehealth paired with a compounding-pharmacy pathway. Its medication choices, pricing tiers, and clinical touchpoints are defined on Brello's own website and can shift over time, so treat that page as the authoritative source when you compare the two programs.

Coverage, cash-pay, and what shapes your cost

Because Mochi builds in insurance support, your out-of-pocket amount can depend on your plan, prior authorization, and product choice. Brello's cash-pay compounded model tends to be more uniform but rarely touches insurance. Compounded GLP-1 therapy is generally not covered, so verify each program's current pricing and any coverage terms directly before deciding.

The pharmacology stays the same either way

No matter which access model you choose, the biology is fixed. GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide act on satiety, appetite signaling, and gastric emptying. That effect comes from the compound, so neither Mochi's insurance angle nor Brello's compounded focus changes how the medication works in the body.

The upstream variable both leave out

Neither program reads the inherited biology under your response. A common FTO variant influences appetite and fat-mass regulation, MC4R governs satiety signaling, and TCF7L2 connects to glucose handling and GLP-1 secretion. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights across that terrain — describing your baseline rather than predicting how any specific medication will perform.

How PlexusDx frames the choice

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, with Semaglutide Injection at $189/month and Tirzepatide Injection at $289/month. Pairing the protocol with the Precision Peptide Genetic Test puts your pathway data first — the test-before-you-invest sequence that an insurance-support or cash-pay program alone does not provide.

No affiliation: PlexusDx is unaffiliated with Mochi Health and Brello and has no commercial tie to either.

More from PlexusDx: GLP 1 Drugs, GLP 1 Hormone, GLP 1 Receptor Agonist, and GLP 1 What Is.

Editorial note: this comparison is educational and independent. PlexusDx has no relationship with Mochi Health or Brello and sells semaglutide and tirzepatide through its own protocols. The Precision Peptide Genetic Test analyzes gene-influenced peptide pathways and does not predict drug response. Consult a qualified healthcare provider before starting any peptide protocol.

Frequently Asked Questions

Does Mochi Health or Brello work better with insurance?

Mochi Health is built around insurance support, so a compatible plan may reduce cost, while Brello centers on cash-pay compounded medication that rarely involves insurance. Coverage depends heavily on your plan and the product chosen, so confirm current terms on each brand's own website before enrolling.

Is compounded GLP-1 medication ever covered?

Compounded semaglutide and tirzepatide are usually cash-pay and not reimbursed by insurance, which is why programs like Brello price them directly. FDA-approved branded products are more likely to involve coverage under some plans. Verify specifics with your insurer and the program before assuming any reimbursement.

Which program costs less overall?

There is no fixed answer. An insurance-support model can be cheaper with the right plan but variable without one, while a cash-pay compounded model is more predictable yet fully out of pocket. Compare each program's posted pricing against your own coverage before deciding which is more economical.

Does the genetic test change my coverage options?

No. The Precision Peptide Genetic Test has nothing to do with insurance and does not predict medication response. It maps pathway variants like FTO and MC4R that describe your metabolic baseline, giving you context to discuss with a provider regardless of which access model you choose.

This article is part of the PlexusDx Education Hub. Browse more Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.